Lung cancer epigenetics: From knowledge to applications.

[1]  E. Brambilla,et al.  Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.

[2]  David C. Smith,et al.  Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors , 2017 .

[3]  K. Kelly,et al.  Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. , 2017, The Lancet. Oncology.

[4]  D. MacPherson,et al.  Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance) , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  Jang-Ming Lee,et al.  Identification of Methylation-Driven, Differentially Expressed STXBP6 as a Novel Biomarker in Lung Adenocarcinoma , 2017, Scientific Reports.

[6]  Shumei Feng,et al.  Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer , 2017, Scientific Reports.

[7]  C. Rudin,et al.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.

[8]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[9]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[10]  D. Wheeler,et al.  SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers , 2017, Nature Communications.

[11]  Linlang Guo,et al.  Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2 , 2017, Molecular Cancer.

[12]  B. Qian,et al.  Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung Cancer , 2016, Scientific Reports.

[13]  J. Herman,et al.  Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum , 2016, Clinical Cancer Research.

[14]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[15]  J. Choi,et al.  Histone variant H3F3A promotes lung cancer cell migration through intronic regulation , 2016, Nature Communications.

[16]  Peter A. Jones,et al.  Targeting the cancer epigenome for therapy , 2016, Nature Reviews Genetics.

[17]  D. Pastuszak-Lewandoska,et al.  FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer. , 2016, International journal of oncology.

[18]  K. J. Grande-Allen,et al.  ZEB1 Induces LOXL2-Mediated Collagen Stabilization and Deposition in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis , 2016, Oncogene.

[19]  Xuefei Shi,et al.  Downregulation of the long noncoding RNA GAS5-AS1 contributes to tumor metastasis in non-small cell lung cancer , 2016, Scientific Reports.

[20]  Yiling Lu,et al.  Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer , 2016, Oncogene.

[21]  Alicia N. Schep,et al.  Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility , 2016, Cell.

[22]  Mats Lambe,et al.  Profiling cancer testis antigens in non-small-cell lung cancer. , 2016, JCI insight.

[23]  A. Shaw,et al.  Resisting Resistance: Targeted Therapies in Lung Cancer. , 2016, Trends in cancer.

[24]  R. Siebert,et al.  Downregulation of the TGFβ Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGFβ Signaling and Invasion. , 2016, Cancer research.

[25]  B. Lim,et al.  Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression , 2016, Nature Communications.

[26]  F. Kaye,et al.  cAMP/CREB-regulated LINC00473 marks LKB1-inactivated lung cancer and mediates tumor growth. , 2016, The Journal of clinical investigation.

[27]  F. Hansen,et al.  HDAC5 controls the functions of Foxp3+ T‐regulatory and CD8+ T cells , 2016, International journal of cancer.

[28]  E. Haura,et al.  HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[29]  Michael Q. Zhang,et al.  Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  W. Han,et al.  Genome Wide Methylome Alterations in Lung Cancer , 2015, PloS one.

[31]  P. Vineis,et al.  Hypomethylation of smoking-related genes is associated with future lung cancer in four prospective cohorts , 2015, Nature Communications.

[32]  Zhongming Zhao,et al.  MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer. , 2015, The Journal of clinical investigation.

[33]  Y. Tao,et al.  The ratio of FoxA1 to FoxA2 in lung adenocarcinoma is regulated by LncRNA HOTAIR and chromatin remodeling factor LSH , 2015, Scientific Reports.

[34]  T. Jacks,et al.  Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development. , 2015, Cancer discovery.

[35]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[36]  Le Zhang,et al.  Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/β-catenin signalling , 2015, Nature Communications.

[37]  J. Alcaraz,et al.  Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts , 2015, Carcinogenesis.

[38]  Dong Sun Kim,et al.  MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting insulin receptor substrate 2. , 2015, International journal of oncology.

[39]  J. Kurie,et al.  BMP4 depletion by miR-200 inhibits tumorigenesis and metastasis of lung adenocarcinoma cells , 2015, Molecular Cancer.

[40]  Jianguo Song,et al.  Epigenetic regulation of Smad2 and Smad3 by profilin-2 promotes lung cancer growth and metastasis , 2015, Nature Communications.

[41]  Kathleen R. Cho,et al.  Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy , 2015, Nature.

[42]  K. Walter,et al.  Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer , 2015, British Journal of Cancer.

[43]  C. Croce,et al.  MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer , 2015, Proceedings of the National Academy of Sciences.

[44]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[45]  David Petersen,et al.  An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  Michael S. Goldberg,et al.  Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model , 2015, Cancer Immunology Research.

[47]  Manel Esteller,et al.  Targeting the histone orthography of cancer: drugs for writers, erasers and readers , 2015, British journal of pharmacology.

[48]  Hans Bitter,et al.  Persistence of Smoking-Induced Dysregulation of MiRNA Expression in the Small Airway Epithelium Despite Smoking Cessation , 2015, PloS one.

[49]  D. Xie,et al.  SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway , 2015, The Journal of pathology.

[50]  John T. Poirier,et al.  DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2 , 2015 .

[51]  Jing Wang,et al.  The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers , 2015, Oncogene.

[52]  P. Pinsky.  Cost-effectiveness of CT screening in the National Lung Screening Trial. , 2015, The New England journal of medicine.

[53]  P. Hammerman,et al.  EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumors to TopoII inhibitors , 2014, Nature.

[54]  Jeffrey W. Clark,et al.  Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.

[55]  Vonn Walter,et al.  BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization. , 2014, Cancer research.

[56]  Yi Cao,et al.  MCRS1 overexpression, which is specifically inhibited by miR-129*, promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer , 2014, Molecular Cancer.

[57]  Arash Naeim,et al.  Cost-effectiveness of CT screening in the National Lung Screening Trial. , 2014, The New England journal of medicine.

[58]  Chengping Hu,et al.  Transforming growth factor-β-induced miR‑143 expression in regulation of non-small cell lung cancer cell viability and invasion capacity in vitro and in vivo. , 2014, International journal of oncology.

[59]  S. Jang,et al.  Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes. , 2014, Cancer letters.

[60]  Johan Staaf,et al.  Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome , 2014, Clinical Cancer Research.

[61]  Lixia Diao,et al.  Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression , 2014, Nature Communications.

[62]  Christopher R. Cabanski,et al.  Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer , 2014, Genome Biology.

[63]  Robert Langer,et al.  Small RNA combination therapy for lung cancer , 2014, Proceedings of the National Academy of Sciences.

[64]  K. Kinzler,et al.  Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells , 2014, Journal of Immunotherapy for Cancer.

[65]  Qiang Yu,et al.  EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer. , 2014, Cell reports.

[66]  Xianghuo He,et al.  miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25 , 2014, Molecular Cancer.

[67]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[68]  R. Rosell,et al.  Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. , 2014, Lung cancer.

[69]  Rui Xia,et al.  Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition , 2014, Molecular Cancer.

[70]  P. Forde,et al.  New Strategies in Lung Cancer: Epigenetic Therapy for Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.

[71]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[72]  Jun Zhao,et al.  MiR‐142‐3p represses TGF‐β‐induced growth inhibition through repression of TGFβR1 in non‐small cell lung cancer , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[73]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[74]  J. Herman,et al.  Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer , 2014, Clinical Cancer Research.

[75]  C. Gilles,et al.  Fhit Regulates EMT Targets through an EGFR/Src/ERK/Slug Signaling Axis in Human Bronchial Cells , 2014, Molecular Cancer Research.

[76]  Tao Yu,et al.  MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway , 2014, Oncogene.

[77]  S. Belinsky,et al.  Global identification of genes targeted by DNMT3b for epigenetic silencing in lung cancer , 2014, Oncogene.

[78]  D. Hayes,et al.  Gene Silencing Associated with SWI/SNF Complex Loss during NSCLC Development , 2014, Molecular Cancer Research.

[79]  T. Betsuyaku,et al.  Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: Its correlation with smoking history and chronic obstructive pulmonary disease , 2013, International journal of cancer.

[80]  Martin Dugas,et al.  DNA Methyltransferase Inhibition Reverses Epigenetically Embedded Phenotypes in Lung Cancer Preferentially Affecting Polycomb Target Genes , 2013, Clinical Cancer Research.

[81]  Min Gyu Lee,et al.  KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. , 2013, The Journal of clinical investigation.

[82]  A. Gemma,et al.  MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells , 2013, Molecular Cancer Therapeutics.

[83]  M. Esteller,et al.  A prognostic DNA methylation signature for stage I non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Michael Q. Zhang,et al.  CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[85]  D. Beer,et al.  Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma , 2013, Clinical Cancer Research.

[86]  I. Wistuba,et al.  EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma , 2013, Clinical Cancer Research.

[87]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  Junchao Cai,et al.  miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. , 2013, Cancer research.

[89]  S. Orkin,et al.  Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer , 2013, Nature chemical biology.

[90]  Bradley P. Coe,et al.  EZH2 Promotes E2F-Driven SCLC Tumorigenesis through Modulation of Apoptosis and Cell-Cycle Regulation , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[91]  T Takahashi,et al.  The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells , 2013, Oncogene.

[92]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[93]  M. Esteller,et al.  Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis , 2013, Oncogene.

[94]  M. Esteller,et al.  Epigenetic profiling joins personalized cancer medicine , 2013, Expert review of molecular diagnostics.

[95]  Jingde Zhu,et al.  DNA methylation-mediated repression of miR-886-3p predicts poor outcome of human small cell lung cancer. , 2013, Cancer research.

[96]  G. Gatta,et al.  Cancer prevalence estimates in Europe at the beginning of 2000. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[97]  Takanori Fujita,et al.  PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer , 2013, Scientific Reports.

[98]  D. Aberle,et al.  Results of initial low-dose computed tomographic screening for lung cancer. , 2013, The New England journal of medicine.

[99]  Elisabeth Brambilla,et al.  Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers , 2013, Science Translational Medicine.

[100]  Yih-Leong Chang,et al.  MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1 , 2013, Nature Communications.

[101]  D. Naidich,et al.  Screening for Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[102]  C. Zahnow,et al.  The future of epigenetic therapy in solid tumours—lessons from the past , 2013, Nature Reviews Clinical Oncology.

[103]  A. Noël,et al.  MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines , 2013, Cell Death and Disease.

[104]  Mary Zhang,et al.  Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis. , 2013, The Journal of clinical investigation.

[105]  Paolo Vineis,et al.  Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. , 2013, Human molecular genetics.

[106]  D. Spector,et al.  The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. , 2013, Cancer research.

[107]  A. Jimeno,et al.  A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer , 2013, Investigational New Drugs.

[108]  Junchao Cai,et al.  miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. , 2013, Cancer research.

[109]  T. Liloglou,et al.  DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. , 2012, Cancer research.

[110]  F. Slack,et al.  miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. , 2012, Cancer research.

[111]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[112]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[113]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[114]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[115]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[116]  Didier Frappaz,et al.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[117]  Hidemi Ito,et al.  Integrated analysis of genetic and epigenetic alterations reveals CpG island methylator phenotype associated with distinct clinical characters of lung adenocarcinoma. , 2012, Carcinogenesis.

[118]  S. Lam,et al.  Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression , 2012, Genome research.

[119]  G. Reifenberger,et al.  Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.

[120]  Min Pan,et al.  A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers , 2012, Genome research.

[121]  Sébastien Couraud,et al.  Lung cancer in never smokers--a review. , 2012, European journal of cancer.

[122]  D. Takai,et al.  Genome structure‐based screening identified epigenetically silenced microRNA associated with invasiveness in non‐small‐cell lung cancer , 2012, International journal of cancer.

[123]  H. Allgayer,et al.  MicroRNA‐30a inhibits epithelial‐to‐mesenchymal transition by targeting Snai1 and is downregulated in non‐small cell lung cancer , 2012, International journal of cancer.

[124]  J. Herman,et al.  Defining a Gene Promoter Methylation Signature in Sputum for Lung Cancer Risk Assessment , 2012, Clinical Cancer Research.

[125]  F. Hirsch,et al.  Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[127]  G. Hampton,et al.  DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[128]  S. Koschmieder,et al.  The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[129]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[130]  M. Fiegl,et al.  A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[131]  D. Dietrich,et al.  SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[132]  M. Esteller,et al.  DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer , 2011, Oncogene.

[133]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[134]  Kimberly D. Siegmund,et al.  DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma In Situ, and Lung Adenocarcinoma , 2011, PloS one.

[135]  S. Goodman,et al.  An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA , 2011, Clinical Cancer Research.

[136]  S. Leng,et al.  EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. , 2011, Cancer research.

[137]  Yun Zheng,et al.  Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. , 2011, Cancer letters.

[138]  G. Goodall,et al.  The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. , 2011, The Journal of clinical investigation.

[139]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[140]  P Barbry,et al.  miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity , 2011, Cell Death and Differentiation.

[141]  Zhaoli Chen,et al.  DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer , 2011, Cancer biology & therapy.

[142]  R. Johnstone,et al.  Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies , 2011, Proceedings of the National Academy of Sciences.

[143]  Diane D. Liu,et al.  miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1 , 2010, Molecular Cancer Research.

[144]  E. Vokes,et al.  Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[145]  H. Allgayer,et al.  Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non–Small Cell Lung Cancer , 2010, Molecular Cancer Research.

[146]  W. Rom,et al.  Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR , 2010, Clinical Cancer Research.

[147]  A. Gemma,et al.  F1000 highlights , 2010 .

[148]  E. Dmitrovsky,et al.  MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. , 2010, The Journal of clinical investigation.

[149]  David Sidransky,et al.  Identification of hypermethylated genes associated with cisplatin resistance in human cancers. , 2010, Cancer research.

[150]  J. Coon,et al.  PTEN, RASSF1 and DAPK site‐specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients , 2010, International journal of cancer.

[151]  F. López-Ríos,et al.  IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer , 2010, Oncogene.

[152]  C. Gilles,et al.  Fhit regulates invasion of lung tumor cells , 2010, Oncogene.

[153]  A. Yang,et al.  Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. , 2010, Epigenomics.

[154]  Chih-Yi Chen,et al.  The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. , 2010, The Journal of clinical investigation.

[155]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[156]  F. Slack,et al.  Regression of murine lung tumors by the let-7 microRNA , 2009, Oncogene.

[157]  John T. Powers,et al.  Lin28 Enhances Tumorigenesis and is Associated With Advanced Human Malignancies , 2009, Nature Genetics.

[158]  Fang Liu,et al.  Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. , 2009, Cancer research.

[159]  G. Wilding,et al.  Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[160]  E. Brambilla,et al.  Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. , 2009, American journal of respiratory and critical care medicine.

[161]  Avrum Spira,et al.  MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium , 2009, Proceedings of the National Academy of Sciences.

[162]  E. Brambilla,et al.  Pulmonary preneoplasia – sequential molecular carcinogenetic events , 2009, Histopathology.

[163]  A. Burny,et al.  Evolution of microRNA expression during human bronchial squamous carcinogenesis , 2008, European Respiratory Journal.

[164]  S. Leng,et al.  Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. , 2008, Cancer research.

[165]  P. Massion,et al.  A high-throughput and sensitive method to measure Global DNA Methylation: Application in Lung Cancer , 2008, BMC Cancer.

[166]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  L. Horvath,et al.  DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma , 2008, British Journal of Cancer.

[168]  D. Metzger,et al.  Targeted knockout of BRG1 potentiates lung cancer development. , 2008, Cancer research.

[169]  J. Herman,et al.  Promoter Hypermethylation of Hallmark Cancer Genes in Atypical Adenomatous Hyperplasia of the Lung , 2008, Clinical Cancer Research.

[170]  J. Herman,et al.  Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. , 2008, Carcinogenesis.

[171]  E. Van Cutsem,et al.  Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer , 2008, Investigational New Drugs.

[172]  F. Slack,et al.  The let-7 microRNA reduces tumor growth in mouse models of lung cancer , 2008, Cell cycle.

[173]  Steven Piantadosi,et al.  DNA methylation markers and early recurrence in stage I lung cancer. , 2008, The New England journal of medicine.

[174]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[175]  Phillip A Sharp,et al.  Suppression of non-small cell lung tumor development by the let-7 microRNA family , 2008, Proceedings of the National Academy of Sciences.

[176]  Dong Sun Kim,et al.  Aberrant methylation of E‐cadherin and H‐cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features , 2007, Cancer.

[177]  J. Minna,et al.  Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. , 2007, Cancer research.

[178]  Wendy Cozen,et al.  Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma , 2007, Molecular Cancer.

[179]  C. Morrison,et al.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B , 2007, Proceedings of the National Academy of Sciences.

[180]  G. Giaccone,et al.  Global histone modifications predict prognosis of resected non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[182]  S. Spivack,et al.  Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. , 2007, Cancer research.

[183]  S. Steinberg,et al.  Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin , 2007, Clinical Cancer Research.

[184]  W. Franklin,et al.  Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum , 2007, British Journal of Cancer.

[185]  M. Fraga,et al.  Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. , 2007, Cancer research.

[186]  G. Sozzi,et al.  Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line. , 2007, Cancer letters.

[187]  Jack A. Taylor,et al.  Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells. , 2007, Cancer letters.

[188]  H. Hsu,et al.  Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. , 2007, Lung cancer.

[189]  S. De Flora,et al.  Molecular and cytogenetical alterations induced by environmental cigarette smoke in mice heterozygous for Fhit. , 2007, Cancer research.

[190]  M. Spitz,et al.  Aberrant Promoter Methylation Profile and Association with Survival in Patients with Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[191]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[192]  Ming Zhao,et al.  Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura , 2006, Clinical Cancer Research.

[193]  Y. Shim,et al.  Elevated mRNA levels of DNA methyltransferase‐1 as an independent prognostic factor in primary nonsmall cell lung cancer , 2006, Cancer.

[194]  W. Chapman,et al.  CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer , 2006, Genes, chromosomes & cancer.

[195]  M. Morita,et al.  The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma , 2006 .

[196]  Y. Shim,et al.  Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. , 2006, Cancer research.

[197]  S. Belinsky,et al.  Gene Promoter Hypermethylation in Mouse Lung Tumors , 2006, Molecular Cancer Research.

[198]  J. Herman,et al.  Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. , 2006, Cancer research.

[199]  R. Stephens,et al.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.

[200]  C. Croce,et al.  A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[201]  Y. Yatabe,et al.  A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. , 2005, Cancer research.

[202]  J. Mauderly,et al.  Life-span inhalation exposure to mainstream cigarette smoke induces lung cancer in B6C3F1 mice through genetic and epigenetic pathways. , 2005, Carcinogenesis.

[203]  F. Gilliland,et al.  Gene Promoter Methylation in Plasma and Sputum Increases with Lung Cancer Risk , 2005, Clinical Cancer Research.

[204]  S. Belinsky.  Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. , 2005, Carcinogenesis.

[205]  E. Sausville,et al.  Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[206]  Hisao Asamura,et al.  Promoter Methylation of DAL-1/4.1B Predicts Poor Prognosis in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[207]  J. Califano,et al.  Differential DNA Hypermethylation of Critical Genes Mediates the Stage-Specific Tobacco Smoke-Induced Neoplastic Progression of Lung Cancer , 2005, Clinical Cancer Research.

[208]  F. Slack,et al.  RAS Is Regulated by the let-7 MicroRNA Family , 2005, Cell.

[209]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[210]  Dimitrios Iliopoulos,et al.  Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer , 2005, Oncogene.

[211]  E. J. Lee,et al.  Progressive methylation during the serrated neoplasia pathway of the colorectum , 2005, Modern Pathology.

[212]  J. Park,et al.  DNMT3B polymorphisms and risk of primary lung cancer. , 2004, Carcinogenesis.

[213]  G. Sozzi,et al.  Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line , 2004, Oncogene.

[214]  C. Meijer,et al.  Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. , 2004, Neoplasia.

[215]  David Sidransky,et al.  Genetic and Epigenetic screening for gene alterations of the chromatin‐remodeling factor, SMARCA4/BRG1, in lung tumors , 2004, Genes, chromosomes & cancer.

[216]  Diane D. Liu,et al.  Value of p16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients with Resectable Non–Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[217]  Chih-Yi Chen,et al.  5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer. , 2004, European journal of cancer.

[218]  S. Belinsky,et al.  Gene-promoter hypermethylation as a biomarker in lung cancer , 2004, Nature Reviews Cancer.

[219]  H. Keer,et al.  Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. , 2004, Lung cancer.

[220]  J. Minna,et al.  Synergistic Tumor Suppression by Coexpression of FHIT and p53 Coincides with FHIT-Mediated MDM2 Inactivation and p53 Stabilization in Human Non-Small Cell Lung Cancer Cells , 2004, Cancer Research.

[221]  S. Toyooka,et al.  The relationship between aberrant methylation and survival in non-small-cell lung cancers , 2004, British Journal of Cancer.

[222]  J. Minna,et al.  Dose effect of smoking on aberrant methylation in non‐small cell lung cancers , 2004, International journal of cancer.

[223]  Y. Shim,et al.  Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[224]  S. Belinsky,et al.  Aberrant Promoter Hypermethylation of the Death-Associated Protein Kinase Gene Is Early and Frequent in Murine Lung Tumors Induced by Cigarette Smoke and Tobacco Carcinogens , 2004, Cancer Research.

[225]  J. Minna,et al.  RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. , 2004, Cancer research.

[226]  C. Moon,et al.  Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer , 2004, Clinical Cancer Research.

[227]  J. Herman,et al.  Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. , 2003, Cancer research.

[228]  S. Belinsky,et al.  Carcinogen exposure differentially modulates RAR-beta promoter hypermethylation, an early and frequent event in mouse lung carcinogenesis. , 2003, Carcinogenesis.

[229]  Michael Thomas,et al.  MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer , 2003, Oncogene.

[230]  S. Lam,et al.  Epigenetic down-regulation of death-associated protein kinase in lung cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[231]  J. Verdebout,et al.  Fragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53 , 2003, European Respiratory Journal.

[232]  R. Stahel,et al.  Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation , 2003, Cell Death and Differentiation.

[233]  Hongbing Shen,et al.  A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. , 2002, Cancer research.

[234]  F. Gilliland,et al.  Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. , 2002, Cancer research.

[235]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[236]  C. Croce,et al.  Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[237]  D. Sidransky,et al.  Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. , 2002, Cancer research.

[238]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[239]  John D Minna,et al.  Differential Inactivation of Caspase-8 in Lung Cancers , 2002, Cancer biology & therapy.

[240]  R. Momparler,et al.  Potential of 5-aza-2'-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. , 2001, Lung cancer.

[241]  G. Pfeifer,et al.  The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas , 2001, Oncogene.

[242]  David Sidransky,et al.  Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival , 2001, Oncogene.

[243]  J. Minna,et al.  Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. , 2001, Journal of the National Cancer Institute.

[244]  J. Minna,et al.  5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. , 2001, Cancer research.

[245]  John K. Wiencke,et al.  p16INK4a and Histology-specific Methylation of CpG Islands by Exposure to Tobacco Smoke in Non-Small Cell Lung Cancer , 2001 .

[246]  S. Belinsky,et al.  p16INK4a and β-catenin alterations in rat liver tumors induced by NNK , 2001 .

[247]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[248]  J. Herman,et al.  Predicting lung cancer by detecting aberrant promoter methylation in sputum. , 2000, Cancer research.

[249]  F. Khuri,et al.  Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. , 2000, Journal of the National Cancer Institute.

[250]  G. Schwartsmann,et al.  A Phase I Trial of Cisplatin Plus Decitabine, a New DNA-Hypomethylating Agent, in Patients with Advanced Solid Tumors and a Follow-Up Early Phase II Evaluation in Patients with Inoperable Non-Small Cell Lung Cancer , 2000, Investigational New Drugs.

[251]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[252]  J. Herman,et al.  In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[253]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[254]  J. Minna,et al.  Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. , 1999, Cancer research.

[255]  J. Herman,et al.  Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. , 1999, Journal of the National Cancer Institute.

[256]  J. Yokota,et al.  Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. , 1998, Cancer research.

[257]  C. Croce,et al.  Loss of FHIT function in lung cancer and preinvasive bronchial lesions. , 1998, Cancer research.

[258]  E Gabrielson,et al.  Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[259]  S. Hecht,et al.  Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. , 1998, Chemical research in toxicology.

[260]  K. Bélanger,et al.  Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. , 1997, Anti-cancer drugs.

[261]  S. Baylin,et al.  Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[262]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[263]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[264]  J. Bartek,et al.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.

[265]  J. Minna,et al.  Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. , 1987, The New England journal of medicine.

[266]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[267]  Gang Liu,et al.  miR-196b Is Epigenetically Silenced during the Premalignant Stage of Lung Carcinogenesis. , 2016, Cancer research.

[268]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[269]  Yun Zheng,et al.  Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer. , 2014, Epigenetics.

[270]  M. Maitland,et al.  Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[271]  J. Crowley,et al.  Phase II trial and cost analysis of fazarabine in advanced non-small cell carcinoma of the lung: A southwest oncology group study , 2007, Investigational New Drugs.

[272]  L. Poirier,et al.  Increased expression of hepatic DNA methyltransferase in smokers , 2004, Cell Biology and Toxicology.

[273]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[274]  J. Herman,et al.  Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. , 1999, Cancer research.